Dublin, June 06, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Endometrial Cancer Therapeutics Market By Therapy (Chemotherapy, Hormone Therapy, Radiation Therapy, Surgery), By Enduser (Research Institutes, Hospitals & Clinics), & Pipeline Analysis, Outlook to 2023" report to their offering. The Endometrial Cancer therapeutics market is poised to reach approximately US$ 27 Billion by 2023
In this report, there is in-depthmarket analysis as well as market segmentation of global endometrial cancer therapeutics. The market potential of endometrial cancer therapeutic drugsisestimated considering that these are being tested in clinical trials for endometrial cancer, besides the ones which have already been approved. The depictedendometrial cancer therapeutic drugsare expected to show their complete market potential soon in the coming years. Furthermore, in this report we have structured the information on epidemiology of endometrial cancer in the world. The report also covers pipeline analysis of endometrial cancer therapeutic drugs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments,as well as strategic collaborations that can impact industry's growth. In the end, the report enlists some of the key players in the Endometrial Cancer Therapeutics market including business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses.Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Endometrial Cancer - Epidemiology & Risk Factors 4. Endometrial Cancer Therapeutics - An Introduction 5. Market Dynamics 5.1 Drivers 5.1.1 Rising Global Endometrial Cancer Epidemics 5.1.2 Obesity Fuelling Endometrial Cancer Incidences 5.1.3 Increasing Healthcare Expenditure 5.2 Challenges 5.2.1 High Cost Associated with the Treatment 5.2.2 Increasing Stringency in Regulatory Requirements 6. Endometrial Cancer Therapeutics Market Outlook to 2023 6.1 Market Potential 7. Market Segmentation 8. Endometrial Cancer Therapeutic Drugs Pipeline Analysis 8.1 By Industry 8.2 By Research Collaborations 9. Trends and Developments 9.1 Womb Lining Models for further Endometriosis Investigation 9.2 Whole Exome Sequencing Aiding Identification of Targeted Therapies 9.3 Sentinel Lymph-node Mapping: Less Invasive Method for Staging 9.4 Metformin Holds Promise for Treating Endometrial Cancer 9.5 Adjuvant Chemotherapy Feasible for High Risk Endometrial Cancer 10. Strategic Mergers & Collaborations in the Endometrial Cancer Therapeutics Industry 11. Competitive Assessment
- ArQule, Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffman La Roche Ltd.
- GlaxoSmithKline plc
- Merck KGaA
- Novartis AG
- Sanofi
- Takeda Pharmaceutical Company Limited
For more information about this report visit http://www.researchandmarkets.com/research/t7td8p/global
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Radiography, Surgical Procedures , Uterine Cancer Drugs
